{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:00Z","timestamp":1761630840300,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA70907","2P30CA016672"],"award-info":[{"award-number":["P50CA70907","2P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Counsel of Technological and Scientific Development of the Ministry of Science-CNPq, Technology and Innovation of Brazil","award":["P246042\/2012-5"],"award-info":[{"award-number":["P246042\/2012-5"]}]},{"name":"Foundation for the Support of Research of the State of S\u00e3o Paulo","award":["FAPESP 2013\/14277-4"],"award-info":[{"award-number":["FAPESP 2013\/14277-4"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.humpath.2018.08.026","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T04:27:43Z","timestamp":1536812863000},"page":"177-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"83","author":[{"given":"Juliana","family":"Machado-Rugolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Todorovic","family":"Fabro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ascheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cec\u00edlia","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Muxfeldt","family":"Ab'Saber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Karen","family":"de S\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Aparecida","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Takagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Terra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin Roger","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Luiza","family":"Capelozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.08.026_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non\u2013small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0010","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non\u2013small-cell lung cancer: KCSG-LU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00428-013-1501-6","article-title":"Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology","volume":"464","author":"Rossi","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2018.08.026_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10555-010-9209-4","article-title":"Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation","volume":"29","author":"Suda","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.humpath.2018.08.026_bb0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple non-melanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0040","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/modpathol.2012.125","article-title":"Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung","volume":"25","author":"Grob","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-4-12","article-title":"The molecular basis of lung cancer: molecular abnormalities and therapeutic implications","volume":"4","author":"Massion","year":"2003","journal-title":"Respir Res"},{"key":"10.1016\/j.humpath.2018.08.026_bb0050","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision diagnosis and treatment for advanced non\u2013small-cell lung cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0060","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"Suppl. 5","key":"10.1016\/j.humpath.2018.08.026_bb0065","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non\u2013small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0070","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.semdp.2015.02.019","article-title":"Protein correlates of molecular alterations in lung adenocarcinoma: immunohistochemistry as a surrogate for molecular analysis","volume":"32","author":"Sholl","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0080","series-title":"IARC WHO Classification of Tumours 2015","article-title":"WHO classification of tumours of the lung, pleura, thymus and heart","author":"Travis","year":"2015"},{"key":"10.1016\/j.humpath.2018.08.026_bb0085","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/1535370216632623","article-title":"Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy","volume":"241","author":"Anton\u00e2ngelo","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.humpath.2018.08.026_bb0090","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jtho.2016.08.134","article-title":"Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment","volume":"11","author":"Huynh","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/onc.2008.384","article-title":"PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer","volume":"28","author":"Crane","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2018.08.026_bb0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.humpath.2016.07.007","article-title":"PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung","volume":"58","author":"Kim","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.tranon.2018.04.006","article-title":"Immune prophets of lung cancer: the prognostic and predictive landscape of cellular and molecular immune markers","volume":"11","author":"Catacchio","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0110","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5858\/arpa.2013-0232-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with non\u2013small cell carcinoma of the lung","volume":"138","author":"Cagle","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0120","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.21037\/jtd.2017.10.43","article-title":"Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma","volume":"9","author":"Zhang","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.humpath.2018.08.026_bb0125","article-title":"The frequency and clinical impact of HER2 alterations in lung adenocarcinoma","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.08.026_bb0130","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2018.08.026_bb0135","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-17-1279","article-title":"CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer","author":"Suda","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2018.08.026_bb0140","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-0267","article-title":"MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer","author":"Saigi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.026_bb0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5858\/arpa.2017-0046-OA","article-title":"Next-generation sequencing approach to non\u2013small cell lung carcinoma yields more actionable alterations","volume":"142","author":"Mehrad","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.lungcan.2013.06.012","article-title":"The utility of the proposed IASLC\/ATS\/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations","volume":"81","author":"Tsutaa","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2018.08.026_bb0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.5858\/arpa.2013-0376-OA","volume":"138","author":"Villa","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2018.08.026_bb0160","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/DDDT.S129305","article-title":"Decitabine reverses TGF-\u03b21\u2013induced epithelial-mesenchymal transition in non\u2013small-cell lung cancer by regulating miR-200\/ZEB axis","volume":"11","author":"Zhang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.humpath.2018.08.026_bb0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1183\/09031936.01.00062201","article-title":"Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis","volume":"18","author":"Steels","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.humpath.2018.08.026_bb0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.17116\/patol20157723-9","article-title":"Non\u2013small cell lung cancer: HER2 oncogene status","volume":"77","author":"Kobyakov","year":"2015","journal-title":"Arkh Patol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0175","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.026_bb0180","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/JTO.0b013e3181e77a78","article-title":"Prognostic stratification of stage IIIA pN2 non\u2013small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014)","volume":"5","author":"Grossi","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2018.08.026_bb0185","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1541-7786.MCR-13-0554","article-title":"PTEN is a potent suppressor of small cell lung cancer","volume":"12","author":"Cui","year":"2014","journal-title":"Mol Cancer Res"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718303526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718303526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:35:11Z","timestamp":1758645311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718303526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":37,"alternative-id":["S0046817718303526"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.08.026","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}